
Platform Publications
Delivering on the RNA Revolution
Antibody Oligonucleotide Conjugates (AOC) therapeutics are designed to combine the proven technology of monoclonal antibodies (mAbs) with the precision and potency of oligonucleotide therapies to access previously untreatable tissue and cell types, opening new potential treatments for patients. We have done the experiments and have followed the data to build our AOC platform. We are revolutionizing the RNA therapeutics field by delivering oligonucleotides where they are needed – including beyond the liver.
Publications
Journal of Medicinal Chemistry
Michael Cochran, Isaac Marks, Tyler Albin, Danny Arias, Philip Kovach, Beatrice Darimont, Hanhua Huang, Usue Etxaniz, Hae Won Kwon, Yunyu Shi, Matthew Diaz, Olecya Tyaglo, Arthur Levin, and Venkata Ramana Doppalapudi. Journal of Medicinal Chemistry 2024 67 (17), 14868-14884. DOI: 10.1021/acs.jmedchem.4c00803
Journal of Medicinal Chemistry
Michael Cochran, Danny Arias, Rob Burke, David Chu, Gulin Erdogan, Michael Hood, Philip Kovach, Hae Won Kwon, Yanling Chen, Michael Moon, Christopher D. Miller, Hanhua Huang, Arthur Levin, and Venkata Ramana Doppalapudi. Journal of Medicinal Chemistry 2024 67 (17), 14852-14867. DOI: 10.1021/acs.jmedchem.4c00802
Nucleic Acids Research
Barbora Malecova, Rob S Burke, Michael Cochran, Michael D Hood, Rachel Johns, Philip R Kovach, Venkata R Doppalapudi, Gulin Erdogan, J Danny Arias, Beatrice Darimont, Christopher D Miller, Hanhua Huang, Andrew Geall, Husam S Younis, Arthur A Levin. Nucleic Acids Research, 2023;, gkad415, https://doi.org/10.1093/nar/gkad415
The New England Journal of Medicine
Levin, AA. N Engl J Med 2017;376:1DOI 10.1056/NEJMcibr1613559
The New England Journal of Medicine
Levin, AA. N Engl J Med 2019;380:1DOI: 10.1056/NEJMra1705346